Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 27;13:845193. doi: 10.3389/fimmu.2022.845193

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Zheng, Zheng, Wang, Tao, Huang, Yang, Ouyang, Duan, Zhang, Chen, Xiang, Jin, Fang, Zhou and Liang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Siah2 enhanced antitumor T-cell immunity in a PD-L1–dependent manner. (A), FCM detected the cell membranous PD-L1 level of PCCA#1 and #2. (B, C), CCK8 assay detects the killing of PCAA#1 LV-NC/LV-Siah2 by activated HPBMC in PCCA#1 and PCCA#2 cells. The ratio of PBMC to tumor cell number was 4 to 1, n = 3. (D), CCK8 assay detected the killing of tumor cells by activated HPBMC after Pembrolizumab or 10 µg/mL IgG treatment. PCAA#2-LV-NC/LV-METTL14 were co-cultured in the presence or absence of HPBMC for 24 h at the ratio of HPBMC to tumor cell number of 4 to 1, n = 3. Mean ± SEM of three independent experiments. *P < 0.05; ^#P > 0.05.